Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · S-8 POS

INOTIV INC

SEC Filing

Filed Jul 20, 2026Accepted Jul 20, 2026, 8:05 AM EDTCIK 720154Accession 0001104659-26-084897
Share

Company context

Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.

Historical securities (2)

Recent company filings

  1. 15-12G filingJul 29, 2026
  2. 8-K15D5 filingJul 29, 2026
  3. EFFECT filingJul 27, 2026
  4. EFFECT filingJul 27, 2026
  5. EFFECT filingJul 27, 2026

As-filed source

Primary evidence